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Endothelial-overexpressed LPS-associated factor 1 (EOLA1) is a 
novel gene discovered in an effort to identify genes expressed in endothelial 
cells by activation of lipopolysaccharide. Previous study demonstrates that 
knocking down EOLA1 stimulated interleukin-6 (IL6) and apoptosis in the 
treatment of LPS in human umbilical vein endothelial cells (HUVEC). 
Analysis of the sequence of EOLA1, revealed that it has ASCH (activating 
signal cointegrator-1 homology) domain containing a unique β-barrel fold 
similar to pseudouridine synthase and archaeosine transglycosylase (PUA) 
domain. Because PUA domain is an ancient RNA binding domain, both 
ASCH and PUA domain appear to have arisen from a common RNA binding 
precursor. Here, I report the crystal structure of EOLA1 at 1.7 Å resolution 
by single wavelength anomalous dispersion (SAD) method using 
selenomethionine derivative crystals to solve the phasing problem. I 
demonstrated that EOLA1 could bind with RNA through gel mobility shift 
assay. Based on these results, I propose that EOLA1 is a RNA binding 
domain and would play regulatory roles in transcription or in protection of 
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Endothelial-overexpressed lipopolysaccharide associated factor 1 (EOLA1) is 
a novel gene discovered in an effort to identify genes expressed in endothelial 
cells by activation of lipopolysaccharide (LPS) [1]. The protein is primarily 
expressed in heart, skeletal muscle, kidney, liver, placenta and relatively high 
levels in spleen, colon, small intestine, and cancer cell lines. [2]. Previous 
report indicates that the protein is localized in the nucleus and matrix of 
ECV304 (human umbilical vein endothelial cell line) cells, and may play a 
role as a signal transduction factor [3, 4]. LPS is an endotoxin composed of 
lipid and polysaccharide that is found in the outer layer of most gram-negative 
bacteria. It initiates strong immune response in immune systems and presence 
of LPS could induce septic shock due to severe immune response. The 
endothelial cell is a prime target of the LPS molecule, and vascular 
complications of septic shock due to Gram-negative bacteria are associated 
with endothelial injury [5, 6]. Recent studies indicate that LPS induces 
apoptosis in different types of endothelium such as HUVEC [7, 8]. 
The two-yeast hybrid system showed interaction between EOLA1 and 
metallothionein (MT) -2a, which was demonstrated by co-
immunoprecipitation experiment [1]. MTs are cysteine rich, low molecular 
mass (6-7 kDa) metal binding proteins that are found in many tissues [9]. Main 
2 
biological roles of metallothioneins are: 1) maintenance of the intracellular 
homeostasis of essential transition metals, 2) detoxification of nonessential 
metals and, 3) a protective function against intracellular oxidative stress [10, 
11]. MT2a is present in all organs and further studies revealed that MT2a is 
induced by LPS which is involved in cell proliferation and differentiation [2, 
12]. Previous study shows that EOLA1 could inhibit IL-6 expression and 
apoptosis in LPS treated HUVEC cells which suggests that EOLA1 could play 
a regulatory role in stress such as inflammation [2]. Furthermore, knocking 
down EOLA1 significantly decreased the expression of MT2a which is 
activated by LPS and inhibiting MT2a increased IL-6 expression of LPS 
induced HUVEC cells [2]. These findings demonstrate that EOLA1 plays a 
regulatory role in transcription and protection of HUVEC injury in 
inflammation [2]. 
Sequence analysis of EOLA1 revealed an activating coactivator complex-1 
homology (ASCH) domain, which contains a unique β-barrel fold similar to 
pseudouridine synthase and archaeosine transglycosylase (PUA) domain. 
PUA domain is an RNA binding domain and both ASCH and PUA domains 
appear to have arisen from a common RNA-binding precursor [13]. However, 
the differences in their binding cleft resulted in distinct functional roles and 
thus, ASCH domains are likely to possess RNA-binding site [13]. ASCH 
3 
domain was named after ASC-1, which is a novel transcription coactivator 
molecule of nuclear receptors [14]. Analysis of EOLA1 structure by Dali 
Server revealed structural similarity in the ASCH domain between ASC-1 and 
EOLA1 with Z-score of 12.3.  
To further study the biological role of EOLA1, I have determined its three-
dimensional structure. Full length of EOLA1 was overexpressed with C-
terminal His6-tag in Escherichia coli, purified, and crystallized. Phasing 
problem was solved by using selenomethionine (SeMet)-substituted EOLA1. 
The three-dimensional structure was determined by single wavelength 
anomalous diffraction (SAD). Here, I report the crystal structure of EOLA1, 
elucidating the potential function of the protein. 
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II. MATERIAL AND METHODS 
1. Materials 
Human full-length EOLA1 (158 amino acids) gene synthesis and polymerase 
chain reaction (PCR) primers, which were used for EOLA1 gene amplification, 
were purchased from Bioneer and Cosmogentech (Seoul, Korea), respectively. 
Luria Broth was purchased from LPHA and Kanamycin from BioBasic. 
Restriction enzymes (NcoI and Xho1) and polymerase PrimeSTAR® HS DNA 
Polymerase from Enzynomics and TaKaRa (Korea) respectively. The 
expression vector pET-28a(+) and E.coli Rosetta™ 2(DE3) pLysS competent 
cells were obtained from Novagen (Darmstadt, Germany). Crystal screen 




Full construct of EOLA1 (158 amino acid residues), was amplified by PCR 
using PrimeSTAR® HS DNA Polymerase (TaKaRa). Amplified genes were 
cleaved at Nco1 and Xho1 restriction enzyme sites, which were inserted into 
the Nco1/Xho1-digested expression vector pET-28a(+) (Novagen) with C-
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terminal His6-tag. 
2.2. Overexpression  
The recombinant plasmid was transformed into E.coli Rosetta™ 2(DE3) 
pLysS competent cells. Cells were grown at 310 K and 0.5 mM isopropyl 1-
thio-ß-D-galactopyranoside (IPTG) were added at O.D.600nm of 0.6 in Luria 
Broth culture media containing 30 mg ml-1 kanamycin. When overexpressing 
SeMet-substituted EOLA1 in Rosetta™ 2(DE3) pLysS, I used the M9 cell 
culture medium containing extra amino acids supplemented with SeMet. 
2.3. Purification 
Cell lysis was carried out using a cell disruptor (Sonics, Vibracell VCX750) 
in 50 mL of lysis buffer containing 500 mM Nacl, 20 mM Tris-HCL, 35 mM 
imidazole, pH 7.5 and 1 mM phenylmethylsulfonyl fluoride. The crude lysate 
was centrifugated at 35,000 xg for 60 min at 277 K. The supernatant was 
loaded onto HiTrap Chelating HP column (GE Healthcare) for affinity 
chromatography and eluted with elution buffer (500 mM NaCl, and 1 M 
imidazole, pH 7.5). Sample was further purified by anion exchange 
chromatography (HiTrap 5 mL Q HP, GE Healthcare) and size exclusion 
chromatography (HiLoad 16 600 Superdex 75 pg, GE Healthcare) equilibrated 
with 200 mM NaCl, 10 mM Tris-HCL, pH 7.5. The purified protein was 
concentrated to 10 mg/ml-1. Purification of SeMet-substituted protein was the 
6 
same as above. 
2.4. Crystallization 
EOLA1 crystals used for data collection were grown with 1 μl of protein and 
0.5 μl of solution (0.1 M HEPES, 4.3 M NaCl, pH 7.5) with protein 
concentration of 15.65 mg ml-1 using hanging drop diffusion method. The Se-
Met substituted EOLA1 was also crystallized by using the same reservoir as 
the native crystal.  
2.5. X-ray data collection and structure determination 
Prior to data collection, crystals were cryo-protected by soaking them in 
reservoir solution of 0.1 M HEPES, 4.3 M NaCl, pH 7.5 with 10% glycerol. 
X-ray diffraction data for both native and SeMet crystals were collected at the 
synchrotron BL-7A at the Pohang Accelerator Laboratory. The SeMet-
substituted EOLA1 crystals were also cryo-protected using selenomethionine 
derivative crystals to solve the phasing problem. The native crystal structure 
was solved by single wavelength anomalous dispersion (SAD) method using 
the HKL2000 [15] program package. SAD phases were determined by using 
AUTOSOL of the PHENIX software [16]. Structure of EOLA1 was completed 
by repeated cycles of model building using Wincoot [17] and refinement by 
REFMAC [18]. Refinement steps were monitored using an Rfree value based 
7 
on 5.0% of the independent reflections. 
2.6. Electrophoretic mobility shift assay (EMSA) 
0.1mM of EOLA1 and 0.1mM of tRNA (Yeast tRNA from brewer’s yeast, 
Roche) were incubated in 1:1 ratio for one hour at 4°C. Also, 0.1mM of 
Triosephosphate isomerase from Thermoplasma acidophilum (TaTPI) was 
incubated with 0.1mM of tRNA in 1:1 ratio, which was used as a control for 
this assay.  
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III. Results and Discussion 
1. Cloning  
Full length of human EOLA1 was constructed as a recombinant protein with 
C-terminal His6-tag in pET-28a vector to enable selectivity in purification.  
2. Overexpression and Purification 
To find the E. coli strain most suitable for overexpression of EOLA1, I tested 
11 competent cells for overexpression. Test result showed that EOLA1 was 
most soluble in Rosetta™ 2(DE3) pLysS competent cells. SeMet-substituted 
EOLA1 was also expressed in Rosetta™ 2(DE3) pLysS using M9 cell culture 
medium containing amino acids supplemented with SeMet. The IPTG induced 
cells were harvested by centrifugation at 6,000 g for 10 min at 277 K. The wet 
cell weight about 5.5 g. Centrifugated cells were lysed by sonication and the 
recombinant EOLA1 protein was purified by affinity chromatography, anion 





Figure 1. SDS-Page of expression and solubility test of full-length EOLA1 
at 293 K. 
A) Rosetta™ 2 (DE3) 
B) Rosetta™ 2 (DE3) pLysS 
C) SoluBL21™ 
Lane 1: A, before IPTG induction 
Lane 2: A, after IPTG induction 
Lane 3: A, supernatant fraction 
Lane 4: A, pallet fraction 
Lane M: protein marker 
Lane 5: B, before IPTG induction 
Lane 6: B, after IPTG induction 
Lane 7: B, supernatant fraction 
Lane 8: B, pallet fraction 
Lane 9: C, before IPTG induction 
Lane 10: C, after IPTG induction 
Lane 11: C, supernatant fraction 






Figure 2. Purification profile from the HiTrap chelating HP column 
chromatography 
Elution was performed with 1 M imidazole in 20 mM Tris-HCl at pH 7.5, 






Figure 3. SDS-PAGE analysis of HiTrap chelating HP column fractions 
Lane 1: fraction #5 
Lane 2: fraction #8 
Lane 3: fraction #11 
Lane 4: fraction #13 
Lane 5: fraction #14 
Lane 6: fraction #15 
Lane 7: fraction #16 
Lane 8: fraction #17 
Lane M: protein marker 
Lane 9: fraction #18 
Lane 10: fraction #19 








Figure 4. Purification profile from HiTrap Q HP column 
chromatography 






Figure 5. SDS-PAGE analysis of HiTrap Q HP column fractions 
Lane 1: fraction #8 
Lane 2: fraction #9 
Lane 3: fraction #10 
Lane M: protein marker 








Figure 6. Purification profile from HiLoad 16 600 Superdex 75 pg 
column chromatography 






Figure 7. SDS-PAGE analysis of HiLoad 16 600 Superdex 75 pg 
fractions 
Lane 1: fraction #19 
Lane 2: fraction #20 
Lane 3: fraction #21 
Lane 4: fraction #22 
Lane M: protein marker 
Lane 5: fraction #23 
Lane 6: fraction #24 




After purification, protein was concentrated to 15.65 mg ml-1 and crystallized 
using the hanging drop diffusion method at 295 K using the reservoir of 0.1 M 
HEPES, 4.3 M NaCl, at pH 7.5. SeMet substituted EOLA1 crystals were 
obtained by using the same conditions as above. 
 
 
Figure 8. Native EOLA1 protein crystal 
 
Figure 9. SeMet-substituted EOLA1 protein crystal 
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4. X-ray data collection and structure determination 
X-ray diffraction data for native EOLA1 crystal was collected to 1.71 Å at the 
synchrotron BL-7A at the Pohang Accelerator Laboratory. Native crystals 
belong to space group P41212 with unit cell parameters of a = 49.8 Å, b = 49.8 
Å, c = 175.7 Å, and β = 90°. Table 1 provides the summary of data collection 
on native EOLA1 crystal. 
 
Figure 10. X-ray diffraction image from native EOLA1 crystal  
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Table1 1. Data collection statistics for native EOLA1 
Data collection  Human EOLA1 
Space group 
a, b, c (Å), β (°) 
P41212 
49.8, 49.8, 175.7, 90 
Data set  
X-ray wavelength (Å) 
Resolution (Å)a 










Rworkc / Rfreed (%) 
Ramachandran plot analysis (%) 
Most favored regions 
Additional allowed regions 
Outliers 
50-1.71 






aValues in parentheses indicate the highest resolution shell 
bRmerge = ΣhΣ i |I(h) i−<I(h)>| / ΣhΣ i I(h)I, where I(h) is the intensity of reflection h, 
and Σh is sum of overall reflection, and Σ i is the sum over i measurement of reflection 
h.  
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5. Electrophoretic mobility shift assay (EMSA)  
To examine the tRNA binding affinity of EOLA1, EMSA was performed by 
incubating EOLA1 and 0.1mM of yeast tRNA mixture in 1:1 ratio for one hour 
at 4°C. For control of this assay, 0.1mM of Triosephosphate isomerase from 
Thermoplasma acidophilum (TaTPI) was incubated with 0.1mM of tRNA in 
1:1 ratio.  After the incubation, samples were loaded onto agarose gel (1%) 
and gel electrophoresis was initiated for 15 minutes. The result showed that 
there is an interaction between EOLA1 and tRNA in comparison to TaTPI and 
tRNA, which was used as a control in this experiment. The dragged band in 
EOLA1 and tRNA clearly indicate that the protein interacted with the mixture 
of tRNA. In contrast, TaTPI and tRNA mixture showed no significance of 
binding activity showing one clear band of tRNA. However, because tRNA 
mixture was used for the gel mobility shift assay, it seems like more than one 
tRNA with different sizes interacted with EOLA1 causing a broad band in the 
agarose gel. Nonetheless, EMSA confirms that EOLA1 does bind with tRNA 






Figure 11. Electrophoretic mobility shift assay (EMSA) gel result 
Lane 1: EOLA1 
Lane 2: EOLA1 + tRNA mix 
Lane M: DNA marker 
Lane 3: TaTPI 
Lane 4: TaTPI + tRNA 
Lane 5: tRNA 
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6. Overall structure of EOLA1 
The structure of human EOLA1 was determined at 1.71 Å resolution by Single 
wavelength anomalous dispersion (SAD) using selenomethionine derivative 
crystals to solve the phasing problem. Final model of EOLA1 consist of five 
α-helices (αA-αE) and six β-sheets (β1- β6).  
 
Figure 12. Overall structure of EOLA1  
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7. Structure analysis 
Sequence analysis of EOLA1 revealed an activating signal 
cointegrator-1 homology (ASCH) domain, which contains a unique β-barrel 
fold similar to pseudouridine synthase and archaeosine transglycosylase (PUA) 
domain. ASCH domain was named after ASC-1, which is a novel transcription 
coactivator molecule of nuclear receptors [14]. PUA domain is an RNA 
binding domain and both ASCH and PUA domains appear to have arisen from 
a common RNA-binding precursor [12]. However, the differences in their 
binding cleft resulted in distinct functional roles and thus, ASCH domains are 
likely to possess RNA-binding site [12]. In terms of conserved sequences, 
EOLA1 contains a GxKxxxxR (where x is any amino acid) motif (Gly19-
Ile20-Lys21-Thr22-Val23-Glu24-Thr25-Arg26) at the N-terminal domain and 
a GxK motif (Gly19-Ile20-Lys21) in between the core helix and strand-2, 
which are all characteristics of ASCH domain [12]. Most of ASCH domains 
have two conserved residues (E,T,S and R) located next to each other that leads 
to a longer G-x-K-x-[ETS]-x-R motif [15]. PUA domains use the glycine-
containing loop between αA and β1 for RNA interaction and these surfaces are 
often composed of positively charged side chains [11]. Since ASCH conserved 
domain, GxKxxxxR motif is also located in the loop between αA and β1, these 
observations indicate that ASCH will also contact the RNA molecule using the 
23 
glycine-containing loop. Therefore, I suggest that EOLA1 will also use its 
loop located in the GxKxxxxR motif to interact with RNA molecule. 
EOLA1, like all proteins containing ASCH domain, contains a helix 
between strand 1 and strand 2 and two helical segments between strand-4 and 
strand-5 with six β-strands that form a β-barrel. However, unlike most ASCH 
domain containing proteins which contain five β-strands, EOLA1 contains six 
β-strands, which differs from most ASCH domains. Despite this difference, 
the β-barrel folds of EOLA1 is still very similar when compared to other 
proteins containing ASCH domain. ASCH superfamily contains a distinct cleft 
located between the helix and β-strand 2. The GxK motif is located in this cleft 
and forms a positively charged surface [12]. Similar cleft has also been 
observed in the PUA domain which has been predicted to be involved in RNA 
methylase and likely to function as RNA binding surface [16-18]. The GxK 
motif in EOLA1 containing lysine is located between αA and β1 forming a 
cleft with positively charged surrounding surface. This cleft exists in both 
ASCH and PUA domain and is predicted to function as RNA binding surface. 







Figure 13. Sequence analysis of EOLA1 and ASC1 
(A) Sequence alignment of ASC-1 and EOLA1. GxKxxxxR motif is 







Figure 14. GxK motif of EOLA1 
(B) Overall structure of EOLA1. Five alpha helices (αA-αE, purple) are 
shown in purple and six β-sheets (β1- β6, blue) are shown in yellow. The six 
β-sheets form a unique β-barrel shape similar to ASCH domain. (C). GxK 








Figure 15. Electrostatic potential surface of EOLA1.  
(A) Overall surface of electrostatic potential with binding cleft labeled. (B) 
Secondary structure of EOLA1 is shown in cartoon with transparent 
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국 문 초 록 
Endothelial-overexpressed lipopolysaccharide-associated 
factor 1 (EOLA1) 은 lipopolysaccharide의 활성화에 의해 내피 세
포에서 발현된 novel gene이다. 이전 연구결과에 의하면, LPS가 처
리된 human umbilical vein endothelial cells (HUVEC)에서 EOLA1
의 억제는 인터루킨-6 (IL6)와 apoptosis에 영향을 준다.  
Sequence 분석 결과, EOLA1은 pseudouridine synthase and 
archaeosine transglycosylase (PUA) 도메인의 독특한 β-배럴 
fold와 비슷한 구조를 가진 activating signal cointegrator-1 
homology (ASCH) 도메인을 가지고 있음을 알 수 있었다. PUA 도
메인은 ancient RNA 결합 도메인이므로, ASCH와 PUA 도메인은 
같은 RNA 결합 precursor인 것으로 보인다. 본 연구에서는 
EOLA1의 구조를 1.7 Å으로 규명했고 selenomethionine 
derivative 결정을 통한 single wavelength anomalous dispersion 
(SAD)을 사용하여 phasing 문제를 해결했다. EOLA1은 5개의 α-
helix (αA-αE)와 6개의 β-strands (β1- β6)으로 구성되었다. 
EOLA1의 결정 구조 분석 결과 ASC-1과 유사한 β-배럴 fold를 
확인할 수 있었다. 더 나아가 gel mobility shift assay를 통해 
32 
EOLA1이 RNA와 결합을 할 수 있음을 보였다. 이러한 결과를 종
합해 볼 때 본 연구자는 EOLA1이 RNA 결합 도메인이며 
transcription또는 HUVEC 염증 예방을 조절할 것이라고 제시한다. 
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